ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 6 for:    homeopathy | Canada
Previous Study | Return to List | Next Study

A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02086864
Recruitment Status : Recruiting
First Posted : March 13, 2014
Last Update Posted : October 26, 2016
Sponsor:
Collaborators:
Lotte & John Hecht Memorial Foundation
Centre for Addiction and Mental Health
Information provided by (Responsible Party):
Heather Boon, University of Toronto

Brief Summary:

Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder that presents during childhood, with at least some symptoms causing impairment before the age of seven. It is characterized by developmentally inappropriate levels of inattention and/or hyperactive-impulsive behavior, with significant impairment occurring in at least two settings. It affects approximately 5.2 million children in the United States. Homeopathic treatment has been shown to be a promising intervention for ADHD, however the reasons for that effectiveness is unclear. Specifically, it is unclear whether improvement is due to the homeopathic medicine, the consultative process, or other non-specific effects.

This study has 3 primary objectives: 1. to determine if there are any specific effects of homeopathic medicines in the treatment of ADHD, 2. to determine if there any specific effects the homeopathic consultation alone in the treatment of ADHD, and 3. to determine if there is an overall effect of homeopathic treatment (homeopathic medicines plus consultation) in the treatment of ADHD.

This is a three arm study. Participants will be randomized to one of three arms:

Arm 1 (Verum group): a treatment arm where the participant will receive homeopathic consultation plus a homeopathic remedy Arm 2 (Placebo group): a treatment arm where the participant will receive homeopathic consultation plus a placebo remedy Arm 3 (Usual care group): participants will continue with usual care and will not receive homeopathic treatment as part of the study.

Participants enrolled in this study, regardless of which study Arm they are in, may continue with all conventional medications or any other aspect of their current standard of care they are taking as recommended by their usual physician (so long as they are on a stable dose of the conventional ADHD medication for at least 6 weeks prior to beginning the trial). They may also continue to attend regularly scheduled visits with their own health care practitioner(s).

Participants may also start, stop or change the dose of any therapy (including conventional medications) during the study and are asked to report the change to the study team. Thus, the placebo group participants are not different than other participants, except that they will have a homeopathic consultation and a placebo remedy. The use of placebo is specific to homeopathic treatment, to allow for double-blinding, which is recognized to reduce study bias.

Prior to enrolling in the study, those considering participation will undergo a full assessment by a psychiatrist with a specialty in child and youth mental health. This assessment confirms the diagnosis and screens for inclusion/exclusion study criteria. At the same time, the psychiatrist recommends evidence-based therapies to clients including conventional medication. The psychiatrist does not directly treat the client. If medication is recommended and the clients wish to pursue it with their regular physician, they would still be able to enroll in the study if they wanted to, after six weeks of reaching a stable dose.

This study will help our understanding of the treatment process and whether different elements of the intervention have greater or lesser effects.

This study is a follow-up to an open label pilot study of the homeopathic treatment of ADHD using the same study team. Sample size was calculated based on the results of that study.


Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Drug: lactose/sucrose granule (Individualized homeopathic medicine treatment) Drug: Placebo lactose/sucrose pill Behavioral: Homeopathic consultation Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 177 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled Study of Homeopathic Treatment of Children and Youth With Attention Deficit Hyperactivity Disorder
Study Start Date : March 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Sucrose
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Usual care
Active Comparator: Individualized homeopathic medicine treatment
Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
Drug: lactose/sucrose granule (Individualized homeopathic medicine treatment)
The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
Behavioral: Homeopathic consultation
Other Name: Homeopathic case taking (90 minutes)
Placebo Comparator: Unmedicated lactose/sucrose pill
Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
Drug: Placebo lactose/sucrose pill Behavioral: Homeopathic consultation
Other Name: Homeopathic case taking (90 minutes)



Primary Outcome Measures :
  1. Change from baseline in Conners 3 Global Index - Parent [ Time Frame: Baseline and weeks 8, 20, 28 ]

Secondary Outcome Measures :
  1. Change from baseline in Conners ADHD Index Probability score [ Time Frame: Baseline and weeks 8, 20, 28 ]
  2. Change from baseline in Conners Content Scale for Inattention and Hyperactivity/Impulsivity [ Time Frame: Baseline and weeks 8, 20, 28 ]
  3. Change from baseline in Conners DSM-IV-TR Symptom Scale for the ADHD Inattentive and ADHD Hyperactive-Impulsive subtypes [ Time Frame: Baseline and weeks 8, 20, 28 ]
  4. Clinical Global Impression-Improvement scale [ Time Frame: Week 28 ]
  5. Change from baseline in the Pediatric Quality of Life Inventory [ Time Frame: Baseline and weeks 8, 20, 28 ]
  6. Change from baseline in Consultation and Relational Empathy measure [ Time Frame: Baseline and weeks 8, 20, 28 ]
  7. Change from baseline in RTI Provider Support Measure [ Time Frame: Baseline and weeks 8, 20, 28 ]
  8. Change from baseline in the Resiliency Scales for Children & Adolescents - Mastery sub-scale [ Time Frame: Baseline and weeks 8, 20, 28 ]
  9. Change from baseline in Coping Efficacy Scale [ Time Frame: Baseline and weeks 8, 20, 28 ]
  10. Change from baseline in Control Beliefs Inventory - Mastery sub-scale [ Time Frame: Baseline and weeks 8, 20, 28 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • have a diagnosis of attention deficit hyperactivity disorder (and any of the subtypes of the diagnosis) confirmed by study psychiatrist
  • have a minimum baseline score on the Connors 3 scale that is 1.5 standard deviations above the population norm based in the age and sex of the participant as was reported to be most commonly used in ADHD treatment trials
  • are between 6 and 16 years of age
  • are able to ingest medications in liquid or in lactose/sucrose granule form;
  • if currently taking stimulant therapy for ADHD, are on a stable dose for a minimum of 6 weeks prior to beginning the study
  • have an estimated I.Q. within the normal range
  • have parents/guardians who are able to read and write in English

Exclusion Criteria:

  • a diagnosis with an additional mental health disorder including, but not limited to, the following: Conduct Disorder, Autism Spectrum Disorder, Bipolar Disorder, and Major Depressive Disorder
  • any significant suicidality
  • an addiction to any substance
  • taking any other prescription medication aside from a stable dose of ADHD medication
  • a history of head injury (with sequelae), seizures, or organ system damage
  • pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02086864


Contacts
Contact: David Brule, BA, DHMS(Ca) 647 378-8309 david.brule@utoronto.ca

Locations
Canada, Ontario
Riverdale Homeopathic Clinic Recruiting
Toronto, Ontario, Canada, M4J 1N1
Contact: David Brule, BA, DHMS(Ca)    647 378-8309    david.brule@utoronto.ca   
Sub-Investigator: David Brule, BA, DHMS(Ca)         
Sponsors and Collaborators
University of Toronto
Lotte & John Hecht Memorial Foundation
Centre for Addiction and Mental Health
Investigators
Principal Investigator: Heather Boon, PhD University of Toronto

Responsible Party: Heather Boon, Principal Investigator, University of Toronto
ClinicalTrials.gov Identifier: NCT02086864     History of Changes
Other Study ID Numbers: UToronto-29722
079-2013 ( Other Identifier: Centre for Addiction and Mental Health )
First Posted: March 13, 2014    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016

Keywords provided by Heather Boon, University of Toronto:
Attention Deficit Hyperactivity Disorder
ADHD
Homeopathy

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms